论文部分内容阅读
为了解细胞周期蛋白E2(cyclinE2)和存活蛋白(survivin)在急性白血病中基因表达及两者间的相关性,采用逆转录-聚合酶链反应的方法检测了84例成人急性白血病患者(16例复发患者,60例初治患者和8例持续缓解患者)和20例正常人的cyclinE2和survivinmRNA的表达。结果表明:①cyclinE2在急性白血病中表达的阳性率(70.24%)高于对照组(0%);survivin在急性白血病中表达的阳性率(72.62%)高于对照组(30%);②在急性白血病中cyclinE2的表达与survivin的表达呈正相关性,r=0.65;③cyclinE2阳性组缓解率(55.81%)低于cyclinE2阴性组(88.24%),cyclinE2阳性组复发率(41.67%)高于阴性组(20%);复发组cyclinE2表达率在三组中最高,持续缓解组cyclinE2表达率在三组中最低,④cyclinE2在急性髓系白血病患者表达率(59.32%)低于急性淋巴细胞白血病患者的表达率(96%);与发病时白细胞计数未见有统计学意义的相关。结论:首次证实cyclinE2在急性白血病中有异常表达,且对临床预后有不良影响;cyclinE2在急性白血病中的表达与survivin有正相关,提示cyclinE2在急性白血病中有可能作为一种微小残留病变的检测指标。
In order to understand the gene expression of cyclin E2 and survivin in acute leukemia and the correlation between them, 84 adult patients with acute leukemia were detected by reverse transcription-polymerase chain reaction (16 cases Relapse patients, 60 patients with untreated patients and 8 patients with sustained remission) and 20 cases of normal human cyclinE2 and survivin mRNA expression. The positive rate of cyclinE2 expression in acute leukemia (70.24%) was higher than that in control group (0%). The positive rate of survivin in acute leukemia (72.62%) was higher than that in control group (30%). The expression of cyclinE2 in leukemia was positively correlated with the expression of survivin, r = 0.65; ③ The response rate of cyclinE2 positive group (55.81%) was lower than that of cyclinE2 negative group (88.24%), and the recurrence rate of cyclinE2 positive group (41.67%) was higher than that of negative group 20%). The cyclinE2 expression rate in recurrence group was the highest among the three groups. The expression rate of cyclinE2 was the lowest among the three groups in the sustained remission group. ④ The expression rate of CyclinE2 in acute myeloid leukemia (59.32%) was lower than that in acute lymphoblastic leukemia (96%); no correlation with leucocyte count at onset was found. CONCLUSION: CyclinE2 is abnormally expressed in acute leukemia for the first time, and has an adverse effect on clinical prognosis. The expression of cyclinE2 in acute leukemia is positively correlated with survivin, suggesting that cyclinE2 may be used as a minimal residual disease in acute leukemia index.